56 results about "Lichen planopilaris" patented technology

Skin disorders such as, for example, atopic dermatitis, dyshidrosis, eczema, lichen planus, psoriasis, and vitiligo, are treated by applying high doses of ultraviolet light to diseased regions of a patients skin. The dosage employed exceeds 1 MED, an MED being determined for the particular patient being treated, and may range from about 1 MED to about 20 MED or higher. The ultraviolet light has a wavelength within the range of between about 295 nanometers to about 320 nanometers and preferably is between about 300 nanometers and about 310 nanometers. High doses of ultraviolet light are restricted to diseased tissue areas so as to avoid risk of detrimental side affects in healthy skin, which is more susceptible to damage from UV light. Cooling the skin prior to and / or while exposing the skin to the UV light can be used to minimize tissue damage resulting from exposure to the UV light. Higher doses of UV light can therefore be employed without injurious affects.

The invention relates to an oral traditional Chinese medicine for treating skin diseases. The oral traditional Chinese medicine is prepared from radix lithospermi, rhizoma smilacis glabrae, fructus gardeniae, cortex dictamni, common peony roots, radix scrophulariae, rehmanniae radix, isatis indigotica forts, radix sophorae flavescentis, lalang grass rhizome, flos sophorae, radix sileris, puncturevine caltrop fruits, red-rooted salvia roots, ligusticum wallichii, large-leaved gentian, processed polygonum multiflorum, Chinese angelica, white paeony roots and licorice roots. The oral traditional Chinese medicine is a pure traditional Chinese medicine prescription, reduces the recurrence rate of psoriasis and obviously improves the cure rate. In the invention, by mixing the Chinese angelica, the white paeony roots, the isatis indigotica forts and the licorice roots for use, the organism immunity can be enhanced greatly and the problem of recurrence of the psoriasis due to cold and pharyngitis can be solved. The oral traditional Chinese medicine has high effective rate to the psoriasis more than 98 percent and also has 100 percent cure rate to conventional skin diseases such as acne, cutaneous pruritus, pityriasis rosea, eczema, lichen planus, neurodermatitis, urticaria, seborrheic dermatitis, and the like.

An ultrasonic toothbrush having spatially extended functionality to treat various oral diseases in addition to removing plaque and treating gingivitis is disclosed. In addition to the ultrasonically activated bristles, the toothbrush incorporates a multi directional ultrasound transducer system, which spatially irradiates the oral cavity with ultrasonic pressure waves, operational to loosen plaque, to remove periodontal bacteria from teeth and gums, and to simultaneously treat and destroy disease causing bacteria and bacterial chains on the inside surfaces of cheeks and lips, providing relief from Recurring Aphthous Stomatitis, Lichen Planus, and Mucositis. Various configurations are disclosed, including user removable and replaceable brush heads and ultrasound treatment heads. A motorized version featuring sonic frequency orbital vibration brush head and bristle tufts is described.

A new topical formulation is provided, with a high chemical stability, of for example a low dose clobetasol propionate, suitable for the topical treatment of skin and mucous membrane conditions associated with disorders including psoriasis, eczema, and other forms of dermatitis and also topical use associated with the mouth, such as lichen planus. The formulation includes an aqueous vehicle of based on propylene glycol as a solvent and moisture-retaining agent, and macrogol-glycerol hydroxystearate as a non-ionic emulsifier, being capable of holding surprisingly low concentrations of clobetasol. The vehicle holds concentrations about 0.005% to about 0.05% by weight of 17-clobetasol propionate, more preferably about 0.02 to 0.025%, even more preferably 0.025% by weight of 17-clobetasol propionate. The formulation has a good chemical stability, resulting in a long durability.

The invention provides a new route of administration for sirolimus, namely that sirolimus is prepared into an external preparation for treating skin diseases. The external preparation is a prescribed preparation or compound preparation containing sirolimus, and the dosage form can be any one of pharmaceutical skin external dosage forms including cream, ointment, gel, spray, coating agent and the like, and can be any one of new external dosage forms including solid lipid nanoparticles and the like. The research shows that the external preparation containing sirolimus can be used for treating multiple immune and inflammatory skin diseases including atopic dermatitis, eczema, dermatitis, lichen planus, psoriasis, vitiligo, rosacea, sarcoidosis and the like, and is good in curative effect, high in safety and free of skin irritation. The external preparation is expected to become an important pharmaceutical preparation for clinically treating skin diseases following corticosteroids.

The present invention relates to caffeic acid analog compounds and methods which may be useful for regeneration, cellular programming, and the treatment of dermatologic, gynecologic, and genital diseases such as inflammatory dermatologic conditions, dysplasia, neoplasia, in situ carcinoma, invasive carcinoma, lichen sclerosus, lichen planus, vaginal dysplasia, vaginal carcinoma, vulvar dysplasia, vulvar carcinoma, cervical dysplasia, cervical carcinoma, and Kaposi's sarcoma.

The invention provides a micro RNA group related to Th17 differentiation. The micro RNA group comprises micro RNA 4426, micro RNA 3615, micro RNA 106b, micro RNA 590 and micro RNA 573. The micro RNA changes remarkably in the Th17 differentiation process and can be used as Th17 control targets for preparing drugs for treating or preventing Th17-related diseases including lupus erythematosus, dermatomyositis, vasculitis, sicca syndromes, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, scleroderma, multiple sclerosis, malaria, solar dermatitis, eczema, leucoderma, psoriasis, atopic dermatitis, lichen planus, diabetes, coronary heart diseases, hyperlipemia and the like. The micro RNA group is sensitive to hydroxychloroquine intervention and can serve as a sensitive index for judgment of the clinical effect of hydroxychloroquine, and the micro RNA is convenient to test clinically and can be rapidly used for judging the clinical effect of hydroxychloroquine.

The invention discloses a pharmaceutical composition for treating oral lichen planus, which is prepared from the following raw materials in parts by weight: 10-60 parts of rhizoma anemarrhenae, 5-50 parts of phellodendron bark, 5-50 parts of radix rehmanniae preparata, 5-50 parts of cornel, 3-30 parts of Chinese yam and 3-30 parts of rhizoma alismatis. The invention also discloses a preparation method and application of the pharmaceutical composition. The pharmaceutical composition has the advantages of novel formula, simple components, low cost, obvious curative effect, no toxic or side effect, low tendency to generating tolerance and the like, and provides a new medicine option for clinically treating patients with oral lichen planus.

The invention relates to mouthwash prepared in a Chinese medical formula, and has the functions of replenishing qi, strengthening the spleen, tonifying the kidney, soothing the nerves, clearing the heat, detoxicating, clearing the damp, reducing the cellular immune response, the capillary permeability and the inflammatory exudates, and improving the immunity of the organism. The invention has the advantages of good treatment effect, high cure rate and no recurrence fundamentally; and the oral drug not only has good preventive effect, but also has good therapeutic effect.

The present invention relates to novel compounds, pharmaceutical compositions and methods for treating tumors, cancer and hyperproliferative diseases including psoriasis, genital warts and hyperproliferative cell growth diseases, including hyperproliferative keratinocyte diseases such as hyperkeratosis, ichthyosis, keratoderma or lichen planus. These compounds are described according to the chemical structure:where R1 is H, OH, F, Cl, Br, I, a C1-C6 optionally substituted alkyl or alkenyl group, an optionally substituted aryl group or a group;Ra is a H, OH, C1-C10, optionally substituted alkyl or alkenyl group, an optionally substituted O—(C1-C7 alkyl group) or O-aryl group, an amine group which is optionally substituted with at least one C1-C10 alkyl group which may be optionally substituted, or a single optionally substituted aryl group, biphenyl group, (C1-C6) alkylenearyl group, (C1-C6) alkylenebiphenyl group, heteroaryl group, heterocyclic group, (C1-C6) alkylene heteroaryl group or (C1-C6) alkylene heterocyclic group;R2 is a group;Rb is a H, OH, C1-C10, optionally substituted alkyl or alkenyl group, an optionally substituted O—(C1-C7 alkyl group) or O-aryl group, an amine group which is optionally substituted with at least one C1-C10 alkyl group which may be optionally substituted, or a single optionally substituted aryl group, biphenyl group, (C1-C6) alkylenearyl group, (C1-C6) alkylenebiphenyl group, heteroaryl group, heterocyclic group, (C1-C6) alkylene heteroaryl group or (C1-C6) alkylene heterocyclic group;R3 and R6 are each independently selected from H, OH, F, Cl, Br, I, a C1-C6 optionally substituted alkyl or alkenyl group, an optionally substituted aryl group, a carbamate, alkylene carbamate, urethane or alkylene urethane;R4 is a group, wherein Rb is as described above; andR5 is a group, wherein Rb is as described above,with the proviso that at least one of R1 and R2 or R4 and R5 contains an Ra or Rb group which is an amine group which is optionally substituted with at least one C1-C10 alkyl group which may be optionally substituted, or a single optionally substituted aryl group, biphenyl group, (C1-C6) alkylenearyl group, (C1-C6) alkylenebiphenyl group, heteroaryl group, heterocyclic group, (C1-C6) alkylene heteroaryl group or (C1-C6) alkylene heterocyclic group;or a stereoisomer, pharmaceutically acceptable salt, solvate, and polymorph thereof.

The invention relates to a drug for treating oral lichen planus, and particularly relates to a traditional Chinese medicine composition made of a plant Chinese herbal medicine as a raw material for treating oral lichen planus. The traditional Chinese medicine composition is characterized by comprising the following crude drugs by weight: 13-19g of honeysuckle, 13-19g of astragalus membranaceus, 10-15g of curcuma zedoary, 10-15g of ligusticum wallichii, 10-15g of coptidis rhizome, 10-15g of caulis sargentodoxae, 10-15g of pinellia ternate, 15-25g of codonopsis pilosula, 3-9g of typhae pollen, and 3-9g of radix glycyrrhizae. The traditional Chinese medicine composition has the beneficial effects that each component of the traditional Chinese medicine adopts a natural traditional Chinese medicine material, so that the traditional Chinese medicine composition is simple in configuration, wide in drug source, and low in cost, has a synergistic effect in drug effect, has the effects of invigorating the spleen and replenishing qi, clearing heat and eliminating dampness, clearing away heat and toxic materials, activating blood circulation and removing blood stasis, dispelling wind and relieving pain and the like, and is significant in effect on treatment of the oral lichen planus.

The invention discloses a traditional Chinese medicine preparation for treating oral mucosa lesions. The traditional Chinese medicine preparation consists of the following raw materials in parts by weight: 10-100 parts of scutellaria baicalensis, 8-80 parts of ligusticum wallichii, 8-80 parts of Angelica sinensis, 8-80 parts of jasmine, 5-60 parts of radix rehmanniae recen, 5-60 parts of semen plantaginis, 5-60 parts of radix curcumae, 5-60 parts of allium macrostemon, 3-30 parts of radix bupleuri, 3-30 parts of felwort and 3-30 parts of codonopsis pilosula. The invention further discloses a preparation method and an application of the traditional Chinese medicine preparation. The experiment proves that the traditional Chinese medicine preparation has good clinical treatment effects on patients suffering from oral mucosa lesions such as oral lichen planus and dental ulcer. The traditional Chinese medicine preparation disclosed by the invention is novel in formula and simple in composition, the price of each main drug is low, the administration cost is low, and the preparation method is easy to operate and controllable in quality and can be suitable for industrial production.

A new topical formulation is provided, with a high chemical stability, of for example a low dose clobetasol propionate, suitable for the topical treatment of skin and mucous membrane conditions associated with disorders including psoriasis, eczema, and other forms of dermatitis and also topical use associated with he mouth, such as lichen planus. The formulation includes an aqueous vehicle of based on propylene glycol as a solvent and moisture-retaining agent, and macrogol-glycerol hydroxystearate as a non-ionic emulsifier, being capable of holding surprisingly low concentrations of clobetasol. The vehicle holds concentrations about 0.005% to about 0.05% by weight of 17-clobetasol propionate, more preferably about 0.02 to 0.025%, even more preferably 0.025% by weight of 17-clobetasol propionate. The formulation has a good chemical stability, resulting in a long durability.

The invention relates to a traditional Chinese medicinal composition for treating oral lichen planus and an application. The composition is prepared from the following traditional Chinese medicinal materials in parts by weight: 8-16 parts of root of pilose asiabell, 8-16 parts of paniculate swallowworf root, 8-16 parts of plantago asiatica, 20-30 parts of coix seed, 20-30 parts of peach seed, 20-30 parts of yam, 12-20 pars of garter snake and 12-20 pars of rhizoma bletillae. The traditional Chinese medicinal composition provided by the invention has an obvious curative effect of treating oral lichen planus and is high in safety.

The invention discloses a medicine for treating mouth ulcer. The primary material of the medicine is saxifrage which can combine with other plants. Said other plants are selected from one or more paddy, pricklyash peel, corn mint, and blumea balsamifera Dc or their mixture. The weight ratio of the saxifrage to other plants is 1:100-100:1. The inventive medicine has a curative effect to the mouth off-flavor generated by mouth microbe community and traumatic ulcer, mouth ulcer generated by the virus or bacteria injury and also can be used for recrudescence mouth ulcer, lichen planus generated by unknown reasons and autoimmune.

An ultrasonic toothbrush having spatially extended functionality to treat various oral diseases in addition to removing plaque and treating gingivitis is disclosed. In addition to the ultrasonically activated bristles, the toothbrush incorporates a multi directional ultrasound transducer system, which spatially irradiates the oral cavity with ultrasonic pressure waves, operational to loosen plaque, to remove periodontal bacteria from teeth and gums, and to simultaneously treat and destroy disease causing bacteria and bacterial chains on the inside surfaces of cheeks and lips, providing relief from Recurring Aphthous Stomatitis, Lichen Planus, and Mucositis. Various configurations are disclosed, including user removable and replaceable brush heads, ultrasound treatment heads, and a system of protecting the vibrating exposed ultrasound transducer from contacting the teeth of the user. A motorized version featuring sonic frequency orbital vibration brush head and bristle tufts is described.

Oral lichen planus (OLP) is an immunologic disease which can be controlled and cleared by topical application of a composition of triamcinolone acetonide 0.1% and retinoic acid 0.05% in Orabase® on the affected areas of the mucosa, thrice daily for three weeks. The combined therapy is more effective than triamcinolone acetonide alone in Orabase®. By this method, clearance can be maintained by less frequent application or lower concentrations of the composition.

The invention relates to a traditional Chinese medicine composition for treating oral lichen planus. An orally taken medicine comprises the following raw materials: 10 to 20 parts of rehmanniae vaporata, 10 to 20 parts of raspberries, 10 to 20 parts of leonurus, 10 to 20 parts of astragalus membranaceus, 10 to 20 parts of rhizoma anemarrhenae, 10 to 20 parts of semen cuscutae, 10 to 20 parts of polygala tenuifolia, 10 to 20 parts of bighead atractylodes rhizomes, 10 to 20 parts of rhizoma cyperi, 10 to 20 parts of scutellaria baicalensis, 10 to 20 parts of glossy privet fruits, 10 to 20 parts of prepared fleece flower roots, 10 to 20 parts of eclipta alba, 10 to 20 parts of medlar, 10 to 20 parts of roots of common peony, 10 to 20 parts of radix ophiopogonis, 10 to 20 parts of herba epimedii, 10 to 20 parts of radix polygonati officinalis, 10 to 20 parts of roots of straight ladybell and 10 to 20 parts of oldenlandia diffusa. An external use medicine comprises the following raw materials: 10 to 20 parts of cutch, 10 to 20 parts of nightshades, 10 to 20 parts of fructus forsythiae, 10 to 20 parts of radix angelicae, 10 to 20 parts of mints, 10 to 20 parts of indigo naturalis, 10 to 20 parts of dandelions, 10 to 20 parts of borneols, 10 to 20 parts of golden cypresses and 10 to 20 parts of oldenlandia diffusa. The pathogenesis of the oral lichen planus is complex, so that therapeutic methods are different from each other, but the effect is undesirable. The research finds that the traditional Chinese medicine composition combined with the immunological therapy is excellent in curative effect in treating the OLP (Oral Lichen Planus), so that the traditional Chinese medicine composition is worthy of popularization and application. The whole formula primarily nourishes liver and kidney and secondarily sooths liver-qi stagnation and purges fire for removing toxin, tonification and purgation are performed in combination, and yin and yang are mutually aided, so that the essential qi in kidney is full, the liver, the spleen, the heart and the lung are moistened and nourished, and the symptom of oral mucosa is improved.

The invention relates to a composition and a method conducive to acquiring follicular regulatory T cells in vitro and an application of the composition. The invention proves that differentiation and number proliferation of in-vitro Tfr (follicular regulatory T cells) can be effectively induced by the aid of irritation of TGF (transforming growth factor)-beta, IL (interleukin)-2, anti-CD3 antibodies, anti-CD28 antibodies and baicalin, and expression of Foxp3 in the Tfr is facilitated. The Tfr cells amplified by the method can be used for treating autoimmune diseases and chronic inflammatory diseases, the autoimmune diseases include lupus erythematosus, dermatomyositis, vasculitides, sicca syndrome, scleroderma, rheumatoid arthritis, ankylosing spondylitis, disseminated sclerosis and autoimmune hepatitis, and the chronic inflammatory diseases include diabetes, coronary heart diseases, hyperlipemia, eczema, vitiligos, atopic dermatitis, lichen planus and the like.

The invention discloses a Chinese herbal compound preparation for treating oral lichen planus and a preparation method thereof and relates to traditional Chinese medicine for treating oral lichen planus and a preparation method thereof. The preparation aims at solving the technical problems that existing traditional Chinese medicine used for treating oral lichen planus is high in treatment cost and unbeneficial to popularization. The Chinese herbal compound preparation is prepared from spina gleditsiae, cortex dictamni, lily, white bombyx batryticatus and fructus forsythia or from spina gleditsiae, caulis spatholobi, cortex dictamni, lily, white bombyx batryticatus and fructus forsythia. According to the preparation method, active pharmaceutical ingredients are soaked in cold water for one hour, and then water is added to boil the ingredients for 30-50 minutes. The Chinese herbal compound preparation is used for treating oral lichen planus.

The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine compound preparation used for preventing recurrent aphthae and application thereof, wherein the traditional Chinese medicine compound preparation is prepared by using Chinese medicines as raw materials. The preparation comprises the following Chinese medicinal herbs in parts by weight: 1-3 parts of rhizome coptisdis, 8-10 parts of capejasmine, 8-10 parts of cortex moutan, 8-10 parts of radix ophiopogonis, 4-6 parts of rhizome cimicifugae, 12-15 parts of rhizome phragmitis and 8-10 parts of raw cattail pollen. The preparation used for preventing recurrent aphthae can be used for treating mouth mucosa diseases, such as oral erosive lichen planus (OLP), chronic glossitis, glossopyrosis syndrome, behcet's diseases and chronic gingivitis.

The invention relates to the field of a traditional Chinese medicine, in particular to an externally applied traditional Chinese medicine for treating oral lichen planus, which is prepared from the following raw material medicines by weight parts: 30g of radix astragali, 15g of radix zanthoxyli, 5g of resina draconis, 15g of borax, 1g of cinnabar and 2g of radix glycyrrhizae; and the medicines are ground and screened by a screen of 100-120 meshes to obtain fine powder, and then the fine powder is filled into a bottle to further use after being sterilized at high temperature. According to the externally applied traditional Chinese medicine, the local drug delivery is carried out, the function is direct and both principal and secondary aspects of disease are treated, so that the externally applied traditional Chinese medicine has the characteristics of short course of treatment, definite curative effect and uneasy relapse; and the cure rate reaches up to 89.29% and the effective ratio reaches up to 96.25%.

The invention provides a medical composition for treating oral mucosa diseases. The medical composition is prepared from the following raw material medicines in parts by weight of 5-50 parts of radixbupleuri, 3-30 parts of rhizoma cimicifugae, 8-80 parts of radix astragali, 3-30 parts of poria cocos, 3-30 parts of ginseng, 3-30 parts of radix glycyrrhizae preparata, 3-30 parts of swordlike atractylodes rhizomes, 3-30 parts of bighead atractylodes rhizomes, 3-30 parts of fructus aurantii, 3-30 parts of rhizoma coptidis, 3-30 parts of radix scutellariae, 3-30 parts of cinnamon and 5-50 parts ofherba cistanches. The invention also further discloses a preparation method and purpose of the medical composition. The traditional Chinese medicine composition provided by the invention is novel informula and simple in composition, has the advantages of being low in cost, notable in treatment effects, free from toxic and side effects and the like, tolerance is not easy to produce, and a new medication selection is provided for clinical treatment of the oral mucosa diseases of oral lichen planus, dental ulcer or chronic periodontitis and the like.

The invention provides ITS primers for amplifying OLP Candida albicans characteristic sequences. The invention is characterized in that: the primers are ITS-1:5'-GGAAGTAAAAGTCGTAACAAGG-3', ITS-2:5'-GCTGCGTTCTTCATCGATGC-3'. The beneficial effects of the invention are mainly as follows: ITS primers for amplifying OLP Candida albicans characteristic sequences are provided, and the ITS primers provides a basis for genotyping of OLP Candida albicans, genuinely provides a reliable basis for the formulation of timely and effective clinical control measures at the gene level and lays a foundation for indepth research on Monilia molecular epidemiology.

The invention discloses a pharmaceutical composition for treating oral patches stria diseases. The pharmaceutical composition is composed of the following raw materials in parts by weight: 5 to 80 parts of rhizoma atractylodis, 5 to 80 parts of bighead atractylodes rhizome, 5 to 80 parts of cimicifuga foetida, 3 to 60 parts of ligusticum wallichii, 3 to 60 parts of myrrh, 3 to 60 parts of peach seed, 3 to 60 parts of round cardamom, 3 to 60 parts of balloonflower root, and 3 to 60 parts of curcuma rhizome. The invention further discloses a preparation method and applications of the pharmaceutical composition. The provided pharmaceutical composition has a good curative effect on oral patches stria diseases such as oral lichen planus, oral leukoplakia, oral erythroplakia, and the like. The pharmaceutical has the advantages of novel formula, simple composition, low cost, prominent curative effect, no side or toxic effect, and difficult generation of drug resistance, and is a novel clinical choice for the patients of oral lichen planus, oral leukoplakia, or oral erythroplakia.

A topical composition is prepared using macerated leaves of St. Andrew's Cross (hypericum hypericoides). An aqueous extract of the leaves is mixed with ethanol to form a spray or to saturate a wet wipe and administer to a mammal skin for treatment a variety of skin conditions, including eczema, psoriasis, rosacea, cellulitis, contact dermatitis, seborrhoeic dermatitis, nummular dermatitis, dandruff, stasis dermatitis, perioral dermatitis, dermatitis herpetiformis, ecthyma, impetigo, shingles, urticaria, tinea pedis, tinea manuum, tinea cruris, sunburn, insect bites and stings, jellyfish stings, granuloma annulare, bullous pemphigoid, lichen planus, bed sore, inflammations caused by waterborne vectors, diaper rash, heat rash, pityriasis rosea, jungle rot, scleroderma, skin rashes and photo-aging.

The invention belongs to the technical field of traditional Chinese medicines, and especially relates to a traditional Chinese medicine formula for treating oral lichen planus. The formula comprises, by weight, 3-5 parts of Melastoma dodecandrum Lour., 2-3 parts of Osbeckia chinensis L., 2-5 parts of Cassia nomame (Sieb.)Kitag., 3-5 parts of Brassica caulorapa, 3-5 parts of root of Ficus comata Hand.-Mazz., 3-5 parts of root and leaf of Crossostephium chinense (L.) Makino, 3-5 parts of Fewflower Lysionotus Herb, 3-5 parts of Artemisia capillaries, 3-6 parts of dasheen petiole, 2-3 parts of Crotalaria ferruginea Grah. ex Benth., 3-5 parts of Semen Euryales, 2-3 parts of tendrilleaf solomonseal rhizome, and 3-5 parts of Polygonatum sibiricum. The formula adopting traditional Chinese medicine conditioning to invigorate spleen, remove dampness, clear heat, detoxify, invigorate and tonify qi, and has a good treatment effect on oral lichen planus.

The invention belongs to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine formula for treating oral lichen planus. The traditional Chinese medicine formula is prepared from the following traditional Chinese medicine raw materials in parts by weight: 3-5 parts of wild hyacinth bean, 2-3 parts of aster fastigiatus, 2-5 parts of all-grass of winkled marshweed, 3-5 parts of cuscuta chinensis, 2-3 parts of kohlrabi, 3-5 parts of ficus comata, 3-5 parts of Japanese clover, 3-5 parts of dodartia orientalis linn, 3-5 parts of cuckoo, 3-6 parts of leea macrophylla roxb.ex hornem, 2-3 parts of centipeda minima, 3-5 parts of potentilla discolor, 2-3 parts of hoary bluebellflower, 3-5 parts of cowpea root and 3-5 parts of unpleasant swallowwort herb. The traditional Chinese medicine formula strengthens the spleen, eliminates dampness, clears away heat and toxic materials, strengthens the spleen and replenishes qi through conditioning of the traditional Chinese medicine and has a better effect for treating the oral lichen planus.

The invention relates to a traditional Chinese medicine preparation, a pharmaceutical composition containing the same, and an application of the traditional Chinese medicine preparation and pharmaceutical composition in the preparation of drugs for preventing or treating oral lichen planus. The traditional Chinese medicine preparation comprises the following components in percentage by weight: 8 to 18% of prepared rehmannia root, 5 to 14% of prepared fleece flower root or polygonatum rhizome, 3 to 12% of ligustrum lucidum, 6 to 16% of yerbadetajo herb, 2 to 11% of ligusticum wallichii, 4 to 14% of Chinese yam, 6 to 15% of America ginseng, 6 to 15% of ginseng, 7 to 16% of lucid ganoderma, 5 to 15% of wolfberry, and 3 to 12% of poria cocos. The provided traditional Chinese medicine preparation or pharmaceutical composition containing the same has a prominent preventive and curative effect on oral lichen planus.